| Previous Section | Index | Home Page |
16 July 2009 : Column 654Wcontinued
Sarah Teather: To ask the Secretary of State for Communities and Local Government what the average private sector rent was in each region of England in (a) 2001-02, (b) 2002-03, (c) 2003-04, (d) 2004-05, (e) 2005-06, (f) 2006-07, (g) 2007-08 and (h) 2008-09. [287689]
Mr. Ian Austin: Estimates of the mean rent for private tenancies by region for the period 1995-96 and 1996-97 to 2006-07 and 2007-08 are available in Housing Statistics live table 734
These estimates are based on data from the Survey of English Housing.
Ms Buck: To ask the Secretary of State for Communities and Local Government how many shared ownership purchases were made in (a) London and (b) England by people registered on housing waiting lists in each year since 2000; and what proportion of all such sales this represented in each such year. [284718]
Mr. Ian Austin: The following table shows the number of shared ownership completions made in London and England by people on housing waiting lists, and as a percentage of total shared ownership sales.
| London | England | |||
| Number of sales | Percentage of sales | Number of sales | Percentage of sales | |
| Source: CORE (Continuous Recording) returns to the Tenant Services Authority (TSA) from Registered Social Landlords (RSLs) | ||||
CORE data only records data from RSLs with at least 250 units or bed spaces, so the figures above may be underestimates if not all RSLs are included. Also not all CORE data is compulsory for RSLs to complete, and details on whether sales were made to people on LA waiting lists was missing in approximately 20 per cent. of returns.
Details on whether shared ownership sales were made to people on LA waiting lists was removed from the CORE form in 2007-08, so the figures are only available up to 2006-07.
Ms Buck: To ask the Secretary of State for Communities and Local Government how much social housing grant was (a) allocated to and (b) bid for by each London local authority in each allocation round since 2000. [284716]
Mr. Ian Austin: Local authorities have been able to apply for social housing grant since 2004, but to date none has. In May we invited local authorities to bid for a share of the £100 million announced in the Budget (with a later addition of up to £250 million) for local authorities to deliver new social housing. The first bids are expected shortly.
Robert Neill: To ask the Secretary of State for Communities and Local Government what post Mr. Tony Clements holds in his Department; and on what date he was appointed. [286645]
Mr. Malik: Tony Clements is a civil servant, working as a policy adviser in the Strategy and Performance Directorate. He was appointed on 29 June 2009.
Andrew Selous: To ask the Secretary of State for Health what monitoring and reviewing of the evidence of the symptoms of radio frequency radiation the Health Protection Agency has undertaken in the last five years; and if he will make a statement. [285575]
Gillian Merron [holding answer 9 July 2009]: The Health Protection Agency (HPA) carries out research on radiofrequency radiation, monitors other studies, and conducts comprehensive reviews of the scientific evidence. The independent Advisory Group on Non-Ionising Radiation (AGNIR) also prepares reviews for the HPA of the evidence for health effects. AGNIR published a review of health effects in relation to radio waves in 2003 (see documents of the NRPB, volume 14, number 2: Health Effects from Radiofrequency Electromagnetic Fields: Report of an independent Advisory Group on Non-ionising Radiation), and the HPA in 2004 (see documents of the NRPB, volume 15, number 3: Review of the Scientific Evidence for Limiting Exposure to Electromagnetic Fields (0-300 GHz)). These publications are both available on the HPA website. AGNIR is commencing another review of the health effects of radio wave exposures, which is expected to take two to three years to complete.
A copy of the report Report 2007 from the independently managed Mobile Telecommunications and Health Research Programme (MTHR), funded by government and industry, has been placed in the Library. None of the studies completed demonstrated that biological or adverse health effects are produced by radiofrequency exposure from mobile phones or base stations. Further research is being carried out to address longer-term exposures and to assess whether hypersensitivity symptoms can be caused by exposure to terrestrial trunked radio (TETRA) signals. Further information on these studies is available on the MTHR website at:
The HPA has concluded that there is no consistent evidence to date that exposure to radio waves from wireless networks adversely affects the health of the general population. Radiofrequency exposures are likely to be lower than those from mobile phones and well within the internationally accepted guidelines from the International Commission on Non-Ionizing Radiation Protection. The HPA keeps the situation under ongoing review. The HPA is carrying out a systematic programme of research into Wireless Local Area Networks and their use, expected to be complete in 2010. Details can be seen on the HPA website at:
www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733726123?p=1171991026241
Jenny Willott: To ask the Secretary of State for Health on what date, and in what location, the documents relating to the infection of haemophiliacs through contaminated blood products released by his Department on 20 May 2009 were discovered; and if he will make a statement. [285741]
Gillian Merron [holding answer 13 July 2009]: The 468 documents released on 20 May 2009 were found in around 40 folders which contained documents from the late 1980s and 1990. These folders were stored at Wellington House, a Department of Health building. While preparing an inventory of these folders in July 2008, departmental officials became aware that they also contained documents relevant to period before 1985 and a full assessment of the content of all the folders was therefore undertaken.
Many of the documents from the relevant period were found to be copies of those already released. There were 469 previously unreleased documents identified, none of which was judged to add materially to the knowledge of events in the years before 1985. One document from this batch was withheld as it contained personal information about a patient. The remaining 468 were released as soon as was practicable.
Jenny Willott: To ask the Secretary of State for Health what the documents relating to the infection of haemophiliacs through contaminated blood products have been requested for release and not released by his Department; on what grounds the documents have not been released; and if he will make a statement. [285851]
Gillian Merron [holding answer 13 July 2009]: Since 1 January 2005, 30 requests have been received under the Freedom of Information Act to release documents relating to the infection of haemophilia patients through contaminated blood products. Eight of these requests were rejected under section 12 of the Act as the cost involved would exceed the statutory cost limit, which is £600 for central Government.
Of the remaining 22 requests, there were 25 instances where documents were withheld from 12 of these requests. The breakdown is as follows:
One instance withheld as exempt from disclosure under section 28;
Two instances withheld as exempt from disclosure under section 34;
Seven instances withheld as exempt from disclosure under section 35;
Two instances withheld as exempt from disclosure under section 36;
Three instances withheld as exempt from disclosure under section 40; and
10 instances withheld as exempt from disclosure under section 43.
Data is not held on the number of individual documents or parts of documents that each withheld instance relates to.
In addition, more than 5,500 documents (including those released on 20 May 2009) covering the relevant time period have been voluntarily released by the Department in line with the Freedom of Information Act. Of these documents, seven, two of which are duplicates, have been withheld under a Freedom of Information exemption because they contain personal information.
Jenny Willott: To ask the Secretary of State for Health which groups of people other than individuals with bleeding disorders his Department has identified who were exposed to potentially contaminated blood and blood products as a result of medical treatment between the 1970s and 1990s; and if he will make a statement. [286475]
Gillian Merron: The groups, in addition to patients with bleeding disorders, who may have been exposed to potentially contaminated blood and blood products received treatment for a range of conditions. These patients include those with primary immunodeficiency who received immunoglobulins, as well as some who required treatment with several infusions of intravenous immunoglobulin G or of plasma, for conditions such as immune thrombocytopaenic purpura or rapid anticoagulation reversal respectively.
Some patients who received transfusions of blood components (red cells, platelets, fresh frozen plasma and cryoprecipitate) before effective tests to screen donated blood for HIV and hepatitis C became available (1985 and 1991 respectively), may also have been exposed.
Recipients of transfusions of blood components may have been exposed to variant Creutzfeldt-Jakob disease (vCJD) during the 1980s and 1990s. To date, four cases of vCJD infection associated with transfusion have been identified, three of which resulted in clinical symptoms in the transfusion recipient. All recipients of blood from the donors to these cases were traced and those living notified of their risk status. Some recipients of plasma products manufactured from United Kingdom sourced pooled plasma between 1980 and 2001 were identified as being potentially at risk for vCJD as a result of their treatment in line with risk assessment advice from the CJD Incidents Panel in 2004.
Jenny Willott: To ask the Secretary of State for Health (1) whether the Department's look back exercise to identify patients who may have been infected with HIV or hepatitis C through blood and blood products will include patients who were at risk of infection but who do not have bleeding disorders; and if he will make a statement; [286477]
(2) when the Department plans to (a) start and (b) finish its look back exercise to identify patients who may have been infected with HIV or hepatitis C as a result of infected blood and blood products, but who are unaware of the fact; and if he will make a statement. [286478]
Gillian Merron: The precise terms and duration of the look-back exercise are due to be finalised imminently with the United Kingdom Haemophilia Centres Doctors Organisation (UKHCDO). It is likely that the look-back exercise will concentrate on patients with bleeding disorders who may have been infected, as indicated in the Government response to Lord Archers independent report into national health service supplied contaminated blood and blood products, but the UKHCDO will also take the opportunity to consider the need to include any other patient groups who may have been infected.
There was a look-back exercise in 1995 to identify and offer hepatitis C testing to recipients of blood transfusions from known hepatitis C infected blood donors. The Departments ongoing hepatitis C awareness campaign, which has been running since 2005, highlights the risks of hepatitis C infection, including specifically from blood transfusions or blood products in the UK before it was possible to introduce safety measures, and encourages patients who may be at risk to discuss the need for testing with their doctor.
Patients infected with HIV through contaminated blood transfusions or blood products in the UK are likely to have already been identified because of the clinical nature of the disease, as it is now over 20 years since HIV testing was introduced by the blood services.
Jenny Willott: To ask the Secretary of State for Health how many partners of haemophiliacs infected with (a) HIV and (b) hepatitis C through contaminated blood products have been infected with (i) HIV and (ii) hepatitis C as a result; and if he will make a statement. [285881]
Gillian Merron: The Department does not hold details of the number of infected partners of haemophiliacs infected with HIV and hepatitis C.
The Macfarlane Trust holds details of the number of partners of HIV infected haemophilia patient registrants, who have become a beneficiary in their own right under the ex-gratia scheme.
The Skipton Fund, who administer the ex-gratia scheme to haemophilia patients and others infected with hepatitis C, does not keep a separate record of the number of people who were infected by their partners.
Jenny Willott: To ask the Secretary of State for Health (1) how many haemophiliacs had tested positive for hepatitis C antibodies in their blood by August 1990 as a result of the application of the Elisa test; and if he will make a statement; [286098]
(2) on what date the (a) first and (b) last haemophiliac was informed of the results of the test for the prevalence of hepatitis C antibodies in their blood from the Elisa test; and if he will make a statement. [286100]
Gillian Merron: This information is not held centrally by the Department. This is a matter for the patient and their clinician, and such information would not necessarily be held by the Skipton Fund.
Mr. O'Hara: To ask the Secretary of State for Health if he will take steps to expedite the adoption of pathogen inactivation measures in order to improve blood safety; and if he will make a statement. [286790]
Gillian Merron: Pathogen inactivation is one of the options the independent Advisory Committee on the Safety of Blood, Tissues and Organs will consider for further reducing the infection risk from platelets (a blood component) at its next meeting in July 2009. There are no pathogen inactivation systems currently available for red cells, the most widely transfused blood component.
| Next Section | Index | Home Page |